X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
3.500
+0.170 (5.11%)
Mar 4, 2026, 4:00 PM EST - Market closed

X4 Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
33.982.56---3
Revenue Growth (YoY)
2925.73%-----
Cost of Revenue
5.70.8----
Gross Profit
28.281.76---3
Selling, General & Admin
51.2861.5235.5127.0224.720.94
Research & Development
75.981.6472.0261.0650.6541.93
Other Operating Expenses
-105-0.519.76-
Total Operating Expenses
127.18248.16107.5288.5985.1162.87
Operating Income
-98.9-246.4-107.52-88.59-85.11-59.87
Interest Income
3.865.774.580.220.010.27
Interest Expense
-8.99-8.77-5.78-3.99-3.64-2.69
Other Non-Operating Income (Expense)
9.242.267.63-2.50.060.31
Total Non-Operating Income (Expense)
4.1-0.746.43-6.27-3.57-2.11
Pretax Income
-94.8-37.14-101.09-93.84-88.68-61.98
Provision for Income Taxes
0.30.310.080.030.020.15
Net Income
-95.1-37.45-101.17-91.32-74.75-62.13
Net Income Attributable to Preferred Dividends
---2.5513.94-
Net Income to Common
-95.1-37.45-101.17-91.32-74.75-62.13
Shares Outstanding (Basic)
1676211
Shares Outstanding (Diluted)
1676211
Shares Change (YoY)
141.07%13.08%179.91%146.71%28.25%74.13%
EPS (Basic)
-10.12-5.70-17.10-45.60-119.70-92.70
EPS (Diluted)
-10.12-5.70-17.10-45.60-119.70-92.70
Free Cash Flow
-107.59-138.23-96.57-77.21-71.52-60.18
Free Cash Flow Per Share
-6.69-20.62-16.29-36.46-83.33-89.92
Gross Margin
82.50%68.83%---100.00%
Operating Margin
-308.29%-9636.33%----1995.80%
Profit Margin
-292.20%-1464.61%----2071.03%
FCF Margin
-330.58%-5405.83%----2006.00%
EBITDA
-99.01-245.61-107.1-88.07-84.61-59.52
EBITDA Margin
-304.21%-9605.20%----1984.10%
EBIT
-98.9-246.4-107.52-88.59-85.11-59.87
EBIT Margin
-308.29%-9636.33%----1995.80%
Effective Tax Rate
-0.32%-0.83%-0.08%-0.03%-0.02%-0.24%
Updated Nov 5, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q